Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Non Operating Income: 2016-2024

Historic Non Operating Income for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to $22.3 million.

  • Autolus Therapeutics' Non Operating Income rose 50.94% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year increase of 204.68%. This contributed to the annual value of $22.3 million for FY2024, which is 177.67% up from last year.
  • As of FY2024, Autolus Therapeutics' Non Operating Income stood at $22.3 million, which was up 177.67% from -$28.7 million recorded in FY2023.
  • Autolus Therapeutics' 5-year Non Operating Income high stood at $22.3 million for FY2024, and its period low was -$28.7 million during FY2023.
  • Its 3-year average for Non Operating Income is -$3.9 million, with a median of -$5.2 million in 2022.
  • As far as peak fluctuations go, Autolus Therapeutics' Non Operating Income plummeted by 456.33% in 2023, and later skyrocketed by 177.67% in 2024.
  • Over the past 5 years, Autolus Therapeutics' Non Operating Income (Yearly) stood at $1.9 million in 2020, then plummeted by 152.33% to -$988,000 in 2021, then tumbled by 422.17% to -$5.2 million in 2022, then crashed by 456.33% to -$28.7 million in 2023, then spiked by 177.67% to $22.3 million in 2024.